Aclaris Therapeutics (ACRS) Price & Analysis

Compare

860 Followers

ACRS Stock Chart & Stats

$2.41

-$0.03(-1.20%)

At close: Jan 08 4:00 PM EST

$2.41

-$0.03(-1.20%)

Day’s Range― - ―

52-Week Range$1.05 - $5.17

Previous CloseN/A

Volume227.82K

Average Volume (3M)1.11M

Market Cap

$255.66M

Enterprise Value$76.62M

Total Cash (Recent Filing)$95.91M

Total Debt (Recent Filing)$2.24M

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Mar 03, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding108,332,214

10 Day Avg. Volume1,094,755

30 Day Avg. Volume1,106,653

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)1.23

Price to Sales (P/S)10.24

P/FCF Ratio-9.49

Enterprise Value/Market Cap0.30

Enterprise Value/Revenue4.87

Enterprise Value/Gross Profit21.60

Enterprise Value/Ebitda-1.22

Forecast

1Y Price Target

$9.25

Price Target Upside283.82% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsAclaris remains positioned to advance clinically on multiple fronts with several key trials progressing.

Financial StabilityThe company ended with cash, cash equivalents, and marketable securities totaling $167.2M, expected to fund operations past multiple key value inflection points.

Promising Drug EfficacyATI-2138 clinical proof-of-concept data looks promising, providing evidence that the drug can offer efficacy comparable to approved treatments with improved tolerability.

Bears Say

Pipeline SkepticismSkepticism exists regarding the Aclaris biologic pipeline, particularly with respect to the targets being addressed by the two lead candidates.

Aclaris Therapeutics News

Aclaris Therapeutics reports Q3 EPS (12c), consensus (14c)

Reports Q3 revenue $3.3M, consensus $1.41M. “Aclaris is advancing a diversified pipeline of product candidates designed to overcome...

8d ago

ACRS

Aclaris Therapeutics: Promising Pipeline and Strategic Financial Management Justify Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics, retaining the price target of...

4d ago

ACRS

Aclaris Therapeutics Reports Q3 2025 Financial Results

Aclaris Therapeutics Inc. ( ($ACRS) ) has released its Q3 earnings. Here is a breakdown of the information...

7d ago

ACRS

ACRS Upcoming Earnings Report: What to Expect?

Aclaris Therapeutics Inc. (ACRS) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street...

11d ago

ACRS

Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis

Aclaris Therapeutics Inc. (($ACRS)) announced an update on their ongoing clinical study. Study Overview: Aclaris Therapeutics Inc. is...

18d ago

ACRS

Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics, retaining the price target of...

25d ago

ACRS

Aclaris Therapeutics Hosts R&D Day for Innovations

Aclaris Therapeutics ( ($ACRS) ) has shared an update. On October 14, 2025, Aclaris Therapeutics will hold an...

1M ago

ACRS

Aclaris Therapeutics to host R&D Day on October 14

Aclaris Therapeutics (ACRS) will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025...

2M ago

ACRS

Promising Phase 2a Results and Strategic Expansion Drive Buy Rating for Aclaris Therapeutics

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics. The associated price target...

3M ago

ACRS

Aclaris Therapeutics Reports Q2 2025 Results and Updates

Aclaris Therapeutics Inc. ( ($ACRS) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

ACRS

Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)

Reports Q2 revenue $1.78M, consensus $1.29M. As of June 30, 2025, Aclaris had cash, cash equivalents and marketable...

3M ago

ACRS

Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements

Thomas Smith, an analyst from Leerink Partners, maintained the Buy rating on Aclaris Therapeutics. The associated price target...

4M ago

ACRS

Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports

In the early hours of the evening session, U.S. equity futures were broadly lower, continuing the regular sessions...

4M ago

CAR

Aclaris announces ATI-2138 trial meets primary, secondary endpoints

Aclaris Therapeutics (ACRS) announced top-line results from its open-label, single-arm Phase 2a trial of ATI-2138 in 14 patients...

4M ago

ACRS

ACRS FAQ

What was Aclaris Therapeutics’s price range in the past 12 months?

Aclaris Therapeutics lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.

What is Aclaris Therapeutics’s market cap?

Aclaris Therapeutics’s market cap is $255.66M.

When is Aclaris Therapeutics’s upcoming earnings report date?

Aclaris Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 109 days.

How were Aclaris Therapeutics’s earnings last quarter?

Aclaris Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.016.

Is Aclaris Therapeutics overvalued?

According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics does not currently pay dividends.

What is Aclaris Therapeutics’s EPS estimate?

Aclaris Therapeutics’s EPS estimate is -0.15.

How many shares outstanding does Aclaris Therapeutics have?

Aclaris Therapeutics has 108,332,214 shares outstanding.

What happened to Aclaris Therapeutics’s price movement after its last earnings report?

Aclaris Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went down -4.237%.

Which hedge fund is a major shareholder of Aclaris Therapeutics?

Currently, no hedge funds are holding shares in ACRS

Aclaris Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-113.23%

Trailing 12-Months

Asset Growth

17.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological conditions and other diseases. The company specializes in novel treatments for skin disorders, particularly its lead product candidates aimed at conditions like alopecia areata and other inflammatory skin diseases. Aclaris leverages its proprietary technology platforms to advance its drug development pipeline, which includes both topical and systemic therapies.

Aclaris Therapeutics (ACRS) Earnings & Revenues

Historic Earnings Reports

ACRS Stock 12 Month Forecast

Average Price Target

$9.25

▲(283.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,3.556923076923077,4.593846153846155,5.630769230769231,6.667692307692308,7.704615384615385,8.741538461538463,9.778461538461539,10.815384615384616,11.852307692307694,12.889230769230771,13.926153846153847,14.963076923076924,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,3.037692307692308,3.5553846153846154,4.073076923076923,4.590769230769231,5.108461538461539,5.626153846153846,6.1438461538461535,6.661538461538461,7.179230769230768,7.696923076923076,8.214615384615385,8.732307692307693,{"y":9.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,2.787692307692308,3.0553846153846154,3.323076923076923,3.5907692307692307,3.8584615384615386,4.126153846153846,4.3938461538461535,4.661538461538461,4.929230769230768,5.196923076923077,5.464615384615385,5.7323076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >